AccuStem Sciences Limited
ACMSYOTCHealthcare
$0.13
$-0.01(-7.14%)
Market Cap$0
P/E Ratio—
52W High$0.13
52W Low$0.12
AccuStem Sciences Limited（ACMSY）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · ACMSY · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.28B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $1.48B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $1.76B | $0.00B | $0.00B | $0.00B | $0.00B |
| Operating Income | ($1.76B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($1.76B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($1.76B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.12 | $-0.13 | $-0.18 | $-0.34 | $-0.07 |
| Wtd Avg Shares | 0.02B | 0.01B | 0.01B | 0.01B | 0.01B |
| EBITDA | ($1.76B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · USD · B
深入了解AccuStem Sciences Limited
关于AccuStem Sciences Limited（ACMSY）损益表
AccuStem Sciences Limited（ACMSY）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，ACMSY实现营收$0.00B，毛利润$0.00B（毛利率—），净利润($1.76B)（净利率—）。
常见问题
ACMSY · 4 问AccuStem Sciences Limited（ACMSY）2025财年营收为$0.00B，同比down—%。
ACMSY revenueACMSY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09